Titlebook: Critical Issues in Head and Neck Oncology; Key concepts from th Jan B. Vermorken,Volker Budach,Brian O‘Sullivan Conference proceedings 2017

Tyler

書目名稱Critical Issues in Head and Neck Oncology影響因子(影響力)




書目名稱Critical Issues in Head and Neck Oncology影響因子(影響力)學(xué)科排名




書目名稱Critical Issues in Head and Neck Oncology網(wǎng)絡(luò)公開度




書目名稱Critical Issues in Head and Neck Oncology網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Critical Issues in Head and Neck Oncology被引頻次




書目名稱Critical Issues in Head and Neck Oncology被引頻次學(xué)科排名




書目名稱Critical Issues in Head and Neck Oncology年度引用




書目名稱Critical Issues in Head and Neck Oncology年度引用學(xué)科排名




書目名稱Critical Issues in Head and Neck Oncology讀者反饋




書目名稱Critical Issues in Head and Neck Oncology讀者反饋學(xué)科排名

百科全書

ck cancer and discussing side effects, survivorship issues and treatment in the elderly, this book?provides and up-to-date coverage of all the critical topics in the field. Highlighting t978-3-319-82691-2978-3-319-42909-0

Entropion

Reclaim

Multidisciplinary Decision Making and Head and Neck Tumor Boardsrs, and (4) the decision of the patient himself/herself. The attitude of the patient in this decision making, being negative or positive, is in that respect extremely important. It has become increasingly apparent that patients need emotional support, not only to navigate through their cancer journe

Tractable

Anecdote

Treatment of Viral-Associated HNC (OPC and NPC)duced compliance to subsequent CCRT remains the biggest drawback to this approach..Current research for HPV+ OPC is refining risk groups and exploring deintensification in low-risk groups and maintaining or augmenting intensification in the high-risk group. Ang et al. constructed two mortality risk

Anecdote

潛移默化

Recurrent/Metastatic Head and Neck Cancer: When and How to Irradiatef reirradiation for recurrent laryngeal cancer). Optimizing the therapeutic ratio of reirradiation requires consideration of several strategies that may facilitate the goal of disease control with reduction of morbidity. The latter may include hyper-fractionation (employing smaller than usual fracti

AXIS

Healthcare System Stakeholders,on, the current role of .F-fluorodeoxyglucose (.F-FDG) PET is addressed, and non-FDG PET tracers including tracers for hypoxia and epidermal growth factor receptor (EGFR) imaging are discussed. We describe development of EGFR imaging with fluorescence and address preclinical imaging results in HNSCC

urethritis